Gene and cell therapy firm Oxford Biomedica is to invest £4 million to build digital and robotics capabilities that will help manufacture the next generation of cutting edge therapies.
Recent breakthroughs in DNA sequencing, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota, an interconnecte